Is 10x Genomics, Inc. (TXG) a Buy, Sell, or Hold?
NASDAQ : TXG
10x Genomics, Inc.
$43.74 USD
-$0.73 (-1.65%)
- Volume
- 2.57M
- Average Volume
- 3.2M
- Market Capitalization
- $5.55B
- P/E Ratio
- -257.29
- Dividend Yield
- 0.00%
- Price Target
- $37.00
- Year High
- $46.32
- Year Low
- $11.16
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.90
Company Overview
NASDAQ
Serge Saxonov
Medical - Healthcare Information Services
Healthcare
TXG
1178
US
USD
Liquidity Metrics
0.10
5.90
5.42
4.32
0.00
Sales & Valuation
$642.82M
8.69
6.89
45.45
0.95
Profitability
-$0.35
-$43.54M
-3.55%
-3.01%
-2.86%
-2.23%
P/E Metrics
-257.29
-1.01
-1.01
Analyst Price Target & Rating
$37.00
$50.00
$17.00
2/5
22 Analysts
18.22%
Poll Results
About 10x Genomics, Inc. (NASDAQ:TXG) Stock
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity ... at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Analyzing Mitesco (OTCMKTS:MITI) and 10x Genomics (NASDAQ:TXG)
2026-07-17 04:23:28
Mitesco (OTCMKTS:MITI - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. Profitability This table compares Mitesco and 10x Genomics' net
10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-15 16:05:00
PLEASANTON, Calif., July 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the second quarter ended June 30, 2026 after market close on Thursday, August 6, 2026.
10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics
2026-06-19 11:36:06
TXG collaborates with the Cleveland Clinic to advance bladder cancer diagnostics using Flex Apex, Xenium and potentially Atera.
Torex Gold Announces Results of Its 2026 Meeting of Shareholders
2026-06-17 17:00:00
Meeting marks formal transition of Andrew Snowden into role of President and CEO Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) (OTCQX: TORXF) announces the results of its 2026 annual and special meeting of shareholders (the "Meeting") held virtually today. The Meeting marked the retirement of Jody Kuzenko and the formal appointment of Andrew Snowden as President and CEO of the Company.
Torex Gold Resources Inc. (TXG:CA) Shareholder/Analyst Call Prepared Remarks Transcript
2026-06-17 11:42:19
Torex Gold Resources Inc. (TXG:CA) Shareholder/Analyst Call Prepared Remarks Transcript
2026-06-17 09:00:00
Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer.
TXG Gains From Proteintech Deal, Expands Multiomics Capabilities
2026-06-10 14:07:04
10x Genomics stock rises after acquiring Proteintech Genomics, adding high-plex proteomics tools that strengthen multiomics research and support platform adoption.
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
2026-06-09 09:00:00
Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the acquisition of Proteintech Genomics, a division within Proteintech Group, a company specializing in developing high-plex proteomic solutions for single cell and spatial applications on 10x platforms.
Frequently Asked Questions
-
What is the current 10x Genomics, Inc. (TXG) stock price?
-
10x Genomics, Inc.(NASDAQ:TXG) stock price is $43.74 in the last trading session. During the trading session, TXG stock reached the peak price of $46.32 while $11.16 was the lowest point it dropped to. The percentage change in TXG stock occurred in the recent session was --1.65% while the dollar amount for the price change in TXG stock was -$0.73.
-
TXG's industry and sector of operation?
-
The NASDAQ listed TXG is part of Medical - Healthcare Information Services industry that operates in the broader Healthcare sector.
-
Who are the executives of TXG?
-
Benjamin J. Hindson | Co-Founder, President, Chief Scientific Officer & Director
Randy Wu | General Counsel and Secretary
Jens Durruthy | Associate Director of Product Management
Jim Goodrich | Chief of Global Operations
Michael Schnall-Levin | Founding Scientist & Chief Technology Officer -
How many employees does TXG have?
-
Number of TXG employees currently stands at 1178. TXG operates from 6230 Stoneridge Mall Road, Pleasanton, CA 94588-3260, US.
-
Link for TXG official website?
-
Official Website of TXG is: https://www.10xgenomics.com
-
How do I contact TXG?
-
TXG could be contacted at phone #925 401 7300 and can also be accessed through its website. TXG operates from 6230 Stoneridge Mall Road, Pleasanton, CA 94588-3260, US.
-
How many shares of TXG are traded daily?
-
The average number of TXG shares traded daily for last 3 months was 3.2M.
-
What is the market cap of TXG currently?
-
The market value of TXG currently stands at $5.55B with its latest stock price at $43.74